COALITION OF SILICONE SURVIVORS

    P. O. Box 129  Broomfield, CO 80038-0129

    Lynda Roth - (303) 469-8242   website: http://www.siliconesurvivors.net

   e-mail: coss@siliconesurvivors.net

December  1998

Dear Silicone Survivors and Friends:

For those of you who have called and sent cards, the biopsy on my remaining

breast was negative.  That is probably not the end of the search since the

blood test (tumor markers) was elevated, but I am relieved for now.  After

I repeat the blood test late in January or early February, I will then know

if I need to do bone scans and an abdominal scan, etc.  I have some local

infection that must be dealt with (no antibiotics that I can take that we

can find), but that, too, will pass. Until then, life as usual!!  Thanks

for all the good thoughts and prayers.  I think they worked.

Because of all the events that are now occurring (mostly legal), we have

made a decision to continue to publish the newsletter.  I think that this

next year will be the end of much of the work on the bankruptcy and the

finalization of much of the class action lawsuit.  We will evaluate again

next December to see if we need to continue.  Please continue to give us

your support and your subscriptions so we can continue to inform you on

what is happening in silicone land (silicone-gate?)

UPCOMING EVENTS:.  No longer upcoming, the National Science Panel has

released its report.  Nothing that helps us was included, at least as far

as I can see.  Here is the AP Release on the Panel's report.  Birmingham,

AL:  A landmark panel of court-appointed scientists said it found no proven

links between silicone breast implants and diseases claimed by women suing

implant manufacturers.  The long-anticipated findings of the independent

committee will help shape the future of U.S. implant litigation because

they can be used in courts nationwide.  The four-member panel, appointed by

U.S. District Judge Sam Pointer of Birmingham to review conflicting

scientific claims, found no definite links between implants and women's

illnesses in four major areas: toxicology, immunology, epidemiology &

rheumatology, the study of diseases of connective tissue such as rheumatoid

arthritis.

"It is our informed opinion that the large majority of scientists in our

respective disciplines would find merit in our reviews and analyses," the

panel reported to Pointer, who oversees thousands of implant cases

nationwide.  There is a possibility that Sjogren's syndrome, marked by

unusual dryness of the mouth, may be linked to silicone from implants, the

panel said, but its symptoms "are nonspecific and relatively common in any

population group."   The report was welcomed by implant companies, which

have spent years and millions of dollars defending themselves against

implant lawsuits.   "This adds to the trend of the past couple of years of

courts rejecting the hypothesis that breast implants cause disease," said

Doug Schoettinger, a lawyer for Dow Corning Corp., once the largest implant

maker.

But Suzanne Turner, a spokeswoman for plaintiff's attorneys, called the

report "terrible news for women."   Sybil Goldrich, an implant recipient

and an activist for fellow recipients who have had problems, faulted the

panel for not looking at the medical records of women who have filed suit

over their implants.  "Nobody looks at those until they get to a

courtroom," she said today.  The panel looked at previously published

studies.  Thousands of women sued manufacturers blaming implants for

sicknesses including lupus, rheumatoid arthritis, body aches, fatigue,

memory loss and hardening of the breasts. Their lawyers contend scientific

studies back up the claims.

Manufacturers deny hurting anyone and point to other studies that found no

links between implants and health problems. They contend women's attorneys

built their cases on flawed science.   Expert panels have reviewed evidence

in previous cases, but never before did a committee have the ability to

affect so many cases nationwide, according to the Washington-based Federal

Judicial Center.  The findings could play a significant role for thousands

of women who sued Dow Corning Corp. Under a proposed $3.2 billion

settlement announced last month, women could either take the money the

company offered (payments would range from $12,000 to $300,000) or continue

their lawsuits. If they continue the lawsuits, the panel's findings could

then be presented as evidence.   "Women will have to make the choice to

litigate or choose the settlement path with full knowledge about what this

panel decided," said Barbara Carmichael, a Dow Corning vice president.

When he announced the creation of the panel in May 1996, Pointer said the

panel could provide "neutral commentary" in videotaped testimony for

federal and state courts. The experts had to be chosen from among those who

had not worked with implant companies or women's attorneys.   Panel members

are immunologist Betty A. Diamond of the Einstein College of Medicine in

New York; epidemiologist Barbara S. Hulka of the University of North

Carolina; rheumatologist Peter Tugwell of the University of Ottawa in

Ontario, Canada; and toxicologist Nancy I. Kerkvliet of Oregon State

University.

The following announcement is from our side: Washington, DC, 12/1/98

PRNewswire: The Command Trust Network, an information clearinghouse for

women with breast implants, issued the following quote from Sybil Niden

Goldrich:  "Nowhere in the report does the Pointer panel say that silicone

is safe in the body. The essential question still has not been resolved:

Why have so many thousands of women been struck with joint pains and

neurological disorders and other health problems after receiving breast

implants? The reason we don't know the answer is because implants were sold

for thirty years without adequate safety testing, as the FDA concluded in

1992 when it banned general sales of implants. Since then the industry has

tried to fill in the huge gap in research with carefully orchestrated

studies meant to improve its legal standing, nothing more. The Pointer

report only proves that the research gap still exists and that we need

reliable government scientists to find trustworthy answers as to why

thousands of women are sick."

Sybil Niden Goldrich received silicone breast implants after a mastectomy

in the 1980s. Persistent ill health led to two implant replacement

operations. The article she wrote for Ms. Magazine in 1986 and her activism

drew widespread public attention and ultimately led to the US FDA

moratorium on silicone breast implants in 1992.  Source:  Command Trust

Network, Inc.

Also from our side: Michael W. Liberman, M.D., Ph.D., Department of

Pathology, Baylor College of Medicine, Houston, Texas 77030 Press

Conference remarks 12/1/98: I want to begin by saying that I think the

panel Judge Pointer convened did an excellent job in sifting through a

voluminous stack of data.  The task was not an easy one and they are to be

commended.  However, I would like to call attention to several important

studies from Baylor College of Medicine that I believe have received

insufficient attention from the panel and one that is scheduled to be

published in April that the panel has not yet seen.  As many of you know,

the material in silicone breast implants is composed primarily of polymer,

that is, high molecular weight compounds that are made up of many repeating

units called monomers.  These polymers form a gel used in implants.  In the

manufacture of polymers the process can be incomplete and result in the

formation of compounds that have only 3 to 20 repeating units instead of

the great number that are present in the polymerized gel.  These incomplete

units are called oligomers or low molecular weight siloxanes.

Research on silicones at Baylor College of Medicine has focused on these

siloxane oligomers.  All the work I am going to tell you about has appeared

or has been accepted for publication in nationally recognized research

journals.  I want to emphasize four significant findings.  First Dr. Ernest

Lykissa and his colleagues have demonstrated that breast implant material

is not pure polymer, but contains these siloxane oligomers.  In addition

the implants contain platinum, the catalyst used to help form polymers from

nonomers.  A second finding of Dr. Lykissa and his colleagues is that these

materials can

migrate out of intact implants.  That is, if an intact implant is placed in

fluid and maintained at body temperature, the siloxane and the platinum can

be found in that fluid.  Simply put, these siloxane oligomers and platinum

can escape through the intact implant capsule into the surrounding

environment.   In a third line of investigation, I have worked with Dr.

Lykissa and others to investigate the fate of these oligomers.  Our results

have demonstrated that these siloxane oligomers, if injected under the skin

of mice, are taken up and deposited in organs of the mice and in their fat.

We have found these compounds in the lymph nodes, uterus, ovary, fat, and

seven other organs.  They persist for at least a year which is

approximately 40% of the life span of a mouse.  They may be present for

longer periods of time, but we have not examined periods longer than one year.

The fourth point I wish to make is that these siloxane oligomers are toxic

to mice.  In fact, they are lethal.  This work has not yet been published.

It is scheduled to appear in the April issue of Environmental Health

Perspectives, the official journal of the National Institute of

Environmental Health Sciences.  Normally, one is not supposed to talk about

unpublished work in public.  But I felt that this work was so important

that I have contacted Dr. Kenneth Olden, the Director of NIEHS, and he has

assured me that there is no conflict if I present this material that is

still in the process of being published.  The story is this: If one injects

these compounds into the abdomen of female mice, they produce severe liver

and lung injury and mice die approximately 7 days after the injection.

We have studied one of these siloxane oligomers, known as D4, in more

detail. Injection of approximately 0.2mi (about 4%of a teaspoon) will kill

approximately 50% of the mice in this time period.  This degree of toxicity

is about the same as that of carbon tetrachloride and triechloroethylene,

two compounds that are widely recognized as model toxins and in fact are

used by many researchers in their work to understand how toxic chemicals

harm the body.  Let me conclude by noting that I believe there is

significant evidence that components of breast implants are highly toxic

and may cause serious health effects.  (The news conference was called by

Congressman Gene Greene.)

LEGAL INFORMATION:  For those who have wondered why GE was dismissed from

all silicone claims, their silicone was clearly marked: NOT INTENDED FOR

BIOLOGICAL USE. The gel they supplied was of industrial quality, not

medical quality, and they clearly "warned" of this on their packaging.  Of

course, medical-grade silicone was much more expensive because it was more

"pure" and Heyer-Schulte chose to use the cheap stuff (they were in this to

make money, not to provide a safe or lasting product, remember) without

"informing" GE that the silicone ultimately wound up in implants. General

Electric claims they did not know that the gel was going into implants, or

other medical devices, as opposed to caulk, pesticides, or other industrial

devices/uses.  Remember that the silicone went through an extensive

chemical process to turn it into the gel that was ultimately used in

implants.  GE had no control over what happened to their silicone once they

supplied it, and supplying silicone in and of itself is not negligent or

illegal. 

For those who may not have registered for the Dow Bankruptcy, this is what

the proposal says: DOW CORNING SETTLEMENT PROGRAM AND CLAIMS RESOLUTION

PROCEDURES  (b) Rule 3005 Claims.  (i) Filing of Notice of Intent.

Claimants who did not timely file a Proof of Claim in the Case but on whose

behalf a Proof of Claim has been timely filed pursuant to Bankruptcy Rule

3005 ("Rule 3005 Claim or Claimant") may file a notice of intent with the

Court as provided in Bankruptcy Rule 3005 to act on her or his own behalf

with respect to such Claim ("Notice of Intent"). Notwithstanding Bankruptcy

Rule 3005, a Rule 3005 Claimant will be entitled to file the Notice of

Intent on or before the date that is 90 days after the Effective Date. Such

Claimant will thereby have all rights as specified in the 3005 filing and

be subject to all deadlines applicable to Claimants who are deemed

registered under (a) above. The Claims of Rule 3005 Claimants who do not

timely file a Notice of  Intent shall be disallowed.

(ii) Submission of Participation Forms. If a Rule 3005 Claimant timely

files a Notice of Intent under paragraph 2.02(b)(i) above and returns a

signed Participation Form to the Claims Office on or before the six-month

anniversary of the Effective Date, as specified in Section 3.02(c) below,

such Claimant will have the right to elect settlement or litigation. Rule

3005 Claimants who do not timely elect litigation or who do not return a

signed Participation Form to the Claims Office on or before the six-month

anniversary of the Effective Date shall be deemed Settling Personal Injury

Claimants for all purposes of this Annex A to the Settlement Facility

Agreement and the Plan.

Also:  Possible good news for those women who did not timely file a proof

of claim in the dow bankruptcy (deadline to file was in January 1997).

Recently Dow Chemical filed co-debtor claims for everyone who ever had a

Dow implant or an implant with any Dow component (ie, gel or shell).  A

woman can "piggy-back" on that Dow filing by using a form called a "Notice

of Intent."  This basically puts the woman into the shoes of Dow Chemical

and allows her to proceed as a timely claimant.  Later, a "Participation

Form" will have to be filed to complete these "substitution" of claimants

from Dow Chemical to the woman.    The Notice of Intent forms are available

from the Tort Claimants Committee. You need to contact the Tort Claimant's

Committee at the law offices of Verner, Liipfert, Bernard, McPherson &

Hand, 1111 Bagby, Ste. 4700, Houston, TX  77002, 713-225-7200, fax

713-752-2199.

Frequently Asked Bankruptcy Questions 1. What am I supposed to do now?  If

you have registered with Daticon in the Dow Corning bankruptcy case and

have received a postcard confirming your registration, you do not need to

do anything right now. When the bankruptcy court approves the materials,

you will receive a package containing the settlement terms.  If you are not

sure whether you have registered in the Dow Corning Bankruptcy case, you

may find out by calling (713) 225-7200 and asking for Pam, Lisa or Ken. If

you are forwarded to voice mail, please leave your name and telephone

number. Note that hundreds of   calls are being received so it may be a day

or two before you get a return call.  If you or your attorney did not

register your claim with Daticon or a late claim was filed on your behalf

in the bankruptcy and assuming the Joint Plan is approved, certain

procedures must be followed in order for you to participate in the plan.

It will be necessary to file a "Notice of Intent" form, a copy of which

will be available at a later date. However, we will need your address in

order to send you additional information regarding these procedures. Please

call (800) 960-6784 to be added to our mailing list. We anticipate that

information on these procedures will be mailed out in the next 30    days.

2. How can I get a copy of the Plan?  An electronic copy of the bankruptcy

plan and other related documents can be obtained from the MDL 926 webpage,

located at:

   http://www.fjc.gov/BREIMLIT/mdl926.htm.

3. What if my implants weren't manufactured by Dow Corning?  If your

implants were manufactured by a company other than Dow Corning, that

purchased silicone gel from Dow Corning, such as Bioplasty, Mentor or

Cox-Uphoff (CUI) and you have not had implants made by any other

manufacturer, you may be able to recover some money from a fund of $57.5

million set aside for disease claims. Claimants who have only Bristol or

Baxter silicone breast implants may apply as well, but they are required to

"marshal" their recoveries (i.e., first obtain all compensation available

to them from the    manufacturer of their implants). Their recovery will be

reduced on a dollar-for-dollar basis. If you have already filed with

Daticon, you need do nothing at this time. If you have not yet registered

or registered late, you will also be required to file a Notice of Intent

form, a copy of which will be available at a later date. We will need your

address in order  to send you additional information regarding these

procedures. Accordingly, please call (800) 960-6784 to be added to our

mailing list. Information on these procedures will be    mailed out on a

weekly basis.  If you have questions or need information about a claim

against your manufacturer, you can call Claims Assistance Counsel at (513)

665-9770.    4. How much money am I going to receive?  At this time, we

cannot answer questions concerning how much money you might receive under

this plan for a number of reasons. However, below you will find a brief

summary of the claims resolution procedures    contained in the documents

filed by Dow Corning and the Tort Claimants' Committee.     5. When might

we receive our money?  We cannot estimate when payments might be made under

this Plan, particularly since the timeline established by the court must

necessarily include a sufficient amount of time in which to vote on the

Plan, as well as allow for other necessary administrative    procedures.

6. How much is my attorney allowed to charge for fees?  Attorneys fees for

all settling defendants are capped and there are some amounts to which a

claimant may be entitled on which an attorney cannot collect fees. The plan

provides in Section 5.10: the fees and expenses of attorneys representing

any of the Settling Personal    Injury Claimants (other than Claimants in

Classes 6A, 6B, 6C and 6D, whose rights shall be governed by the settlement

agreements applicable to those classes) who    receive payment from the

Settlement Facility will be borne by such Claimants based on applicable

state law and the individual arrangements made between them and their

attorneys, subject to the following limitations:         1.The fees charged

by individually-retained              attorneys to a Settling Personal

Injury Claimant shall not exceed the sum of:              (a) 10% of the

first $10,000 paid to such Claimant; (b) 22.5% of the next $40,000 paid to

such Claimant; and (c) 30% of the amount in excess of $50,000 paid to such

Claimant.          2.Amounts paid pursuant to either the Expedited Payment

Option or the Explant Payment Option under the Settlement Facility shall

not be counted as amounts paid to a Settling Personal Injury Claimant for

purposes of this section and no fees              shall be paid with

respect to such amounts.  Particular questions on the bankruptcy settlement

can be answered at: (800) 960-6784. From what has been published so far,

this includes all costs and expenses.  Nothing else except liens can be

charged to the women.  Website for Tort Claimant Committee (TCC):

The same rules on fees and expenses apply to the RSP of the MDL. As to the

actual percentage of attorney fees charged, for those who remained in the

RSP (revised settlement program) of the MDL, fees are restricted to 10% of

the first $10,000, 22.5% up to $50,000 and 30% for amounts over $50,000.

This is the same structure proposed in the Dow Bankruptcy.  Liens signed by

you can be charged back to you, but not expenses for legal services.  If

you were charged more than you should have been in the MDL Revised

Settlement (if your atty. charged you above the percentage listed, ie. for

extra office expenses, etc.) those instances should be reported to the

court (Judge Pointer) and to Ernie Hornsby (he's a plaintiffs' attorney who

has reviewed instances of fee abuse in the RSP).  Ernie's e-mail address

is: ehornsby@ala.net.  You can also reach him at (334) 793-2424.  Your

attorney may be in trouble and may have to refund those extra expenses

charged (to you) 

Women who settled out of the class action often received little or no funds

after their attorneys took out all expenses.  I recently had one woman in

my group who told me that she was billed for $3000 after her settlement.

Her attorney took everything and billed her for more!!!   And she is lucky

to be alive!  Her illnes is severe.  For those who opted out of the

original global and/or RSP and pursued litigation, attorney fees are

dictated by the agreement between the lawyer and client as governed by the

state's rules of professional conduct. Tort Claimants Committee phone # for

bankruptcy inquiries: Plaintiffs' Liaison Counsel Office (800) 960-6784.

MDL 926 Claims office (800) 600-0311.  Dow Corning (800) 222-7198.  Claims

Assistance for  Inamed (CUI, etc.)  (513) 665-9770.

In the Dow Bankruptcy, a person is only eligible for one fund -- either the

Dow Corning Fund or the Silicone Claimant Material Fund.  She cannot

recover from both.  So, if you had a rupture of a Mentor or Bioplasty

implant, you cannot collect for a rupture, only the 40% for the the

Silicone Claimant Material Fund.  This means that they must have a silicone

gel breast implant, it must have been implanted after 1/1/76 and before

1/1/92 and it must be made by either Bristol, Baxter, Bioplasty, Cox-Uphoff

or Mentor. Women who do not qualify for this fund are called Raw Material

Claimants and are treated much differently.  There are no benefits

available to Raw Material Claimants.  Mentor saline implant recipients

would not be eligible for the Silicone Material Claimant Fund.

Silicone injections are not compensated under the proposed Plan.  Persons

with these claims would have to litigate them.  Why they were not covered

is still a question to many of us!! Dow Corning did not supply the silicone

gel to 3M.  Also, the gel in Porex implants came from Koken in Japan.

Toronto Star Staff Reporter (Nicholas Keung): Ontario women with Dow

Corning silicone breast implants are one step closer to claiming $26.4

million in compensation for related illnesses.  An Ontario Court, general

division judge yesterday approved the settlement in a class-action suit

against the implant manufacturer, giving between $10,000 to $100,000 to

some 2,500 women in the province.  Although none of the claimants attended

yesterday's hearing, the decision was hailed by their lawyers and Dow

Corning Corp.  "It's my view....that the settlement is fair, reasonable and

in the best interest to the class members,'' declared Mr. Justice Warren

Winkler in his ruling.  The settlement, part of a $4.9 billion global

package expected to be approved next year, is subject to approval by a

judge and creditors of Michigan-based Dow Corning, which filed for Chapter

11 bankruptcy protection in 1995 because of the crush of implant claims.

If two-thirds of the claimants vote for the Ontario plan after a 60-day

review, they may get paid as soon as next Summer. Winkler pointed to

provisions allowing women who had previously decided not to participate in

the class action to be a part of the settlement.  They are to be

compensated if they develop symptoms as a result of their implants.   Women

who have not experienced any medical problems can choose to cash in a

one-time payment of $1,800.  Lawyer Michael Eizenga, who represented the

Ontario women, said the decision was good news for his clients, who have

claimed implant leaks caused serious diseases of the immune system, as well

as depression and kidney disease. "It means we're nearing the end of a very

long road and I think this settlement will give these women a sense of

closure,'' he said, speaking outside court.  While acknowledging outside

court that the settlement was fair, Dow Corning Canada spokesperson John

Davis said it implies no admission of liability.  All parties are to return

to court in January to appoint a senior official from an insurance company

as claims administrator.

Ottawa, Ontario, Canada: The RCMP (Royal Canadian Mounted Police) has

beefed up a criminal investigation into Health Canada's regulation of

breast implants and a possible cover-up.  "The investigation has been

stepped up," Corporal Marc Richer said.  "It is a serious investigation and

it will be followed through."  Acting on a complaint from a British

Columbia woman, the RCMP assigned one investigator this spring to determine

if Health Canada met its responsibility to make sure silicone gel breast

implants were safe before allowing them on the market.  After interviewing

former Health Canada employees who believe their superiors in the

department's health protection branch ignored warnings for years that the

implants were dangerous, the Mounties determined there is a potential for

criminal charges, Richer said.

Government employees believed their bosses ignored warnings for years.  The

safety of the implants, which Ottawa finally banned in 1993, has been the

subject of intense debate in the medical community and among the estimated

150,000 women in Canada who had the devices inserted.  In August, the RCMP

added two officers and gave its investigative team further clout by

assigning an inspector to head up the investigation. Earlier this month,

the investigators surveyed their material and determined there was enough

substance to the allegations to continue to investigate.  As part of their

efforts, officers travelled to British Columbia to interview the woman who

laid the original complaint.  They also spoke to Linda Wilson, who asked

for an RCMP investigation as far back as 1990 only to be turned down by

then-RCMP commissioner Norman Inkster. Wilson wrote to Inkster complaining

that the Quebec distributor of the

Meme breast implant, Real Laperriere, was allowed to market the foam

covered devices in Canada without proof that they were safe, as required by

the Food and Drugs Act.

The investigation has also broadened beyond breast implants into the health

protection branch's regulation of other medical devices and into the

federal government's awarding of research grants, one source told The Star.

"The investigation is now radiating horizontally into lobbies, it's

radiating into the professional groups, including some surgeons connected

to government," the source said.  "There are a number of other angles." The

Toronto Star, 11/27/98, Laura Eggertson, Ottawa Bureau.

MEDICAL INFORMATION:  Washington, 11/13/98 (Bloomberg): The U.S. Food and

Drug Administration sent a letter to doctors warning that they should be

careful giving an intravenous blood product known as immune globulin to

patients because it may cause kidney problems.  Immune globulin, sold by a

number of companies, is made from donated blood and used to boost the

damaged immune systems of very sick patients. Since becoming available in

1981, immune globulin intravenous use has been associated with 114 reports

of kidney problems around the world, the FDA said.  Most of the time,

doctors were able to treat the problems, though 17 patients died, the FDA

said. Still, many of those patients already had serious health problems,

the agency said.

To minimize the risks, the agency asked doctors to check patients' fluid

levels and assess their kidney function before giving immune globulin. The

agency also advised them to be extra careful when giving it to patients at

risk for kidney failure and not to give a higher dose than is recommended.

There's some evidence that immune globulin preparations that contain

sucrose, such as those distributed by Centeon LLC and Novartis AG, may pose

a higher risk, the FDA said.  "Manufacturers are working with the FDA to

revise their prescribing information to reflect these reports," the agency

said. "The agency is prepared to take further measures in the future as may

be appropriate to ensure product safety." Yoshitomi Pharmaceutical

Industries Ltd's Alpha Therapeutic Corp., Baxter International Inc. and

Bayer AG also sell the immune globulin products, the FDA said.

London, 9/29/98 (Reuters--Jonathan Birt) Scientists have isolated a gene

which they believe acts as an on/off switch for the body's

immune system, promising new ways of treating conditions ranging from

cancer to Crohn's Disease, the British company behind the breakthrough said

on Tuesday.       Researchers at the U.S. arm of Chiroscience Group Plc are

also close to locating a second gene which could reverse bone wasting

caused by osteoporosis, a condition which affects millions of people over

60 and leads to more than one million fractures in the U.S. every year.

Research and Development Director Robert Jackson said uncovering the gene

which regulates the body's immune response could one day lead to

development of a whole new range of drugs.   "Sometimes you want to turn it

off and sometimes you want to turn it on,'' Jackson told Reuters.

Turning the immune sytem on or up could help in conditions like AIDS and

cancer, where the body's efforts to fight off tumours are currently too

weak. "If we could strengthen that, we could develop drugs to help the body

react to tumours,'' Jackson said.  But switching it off or down might be

useful in a range of diseases caused by an overly fierce immune response,

such as rheumatoid arthritis, diabetes, psoriasis, Crohn's Disease,

ulcerative colitis and allergy.  Gene-based research at the former Darwin

Molecular business in Seattle, Washington, which Chiroscience bought in

1996, is also close to locating a mutant gene which may offer a way of

reversing the effects of osteoporosis for the first time.     Scientists

are studying around 100 people and their families in South Africa with

extremely strong bones caused by a mutant gene which causes bone density to

increase as people age, the exact opposite of osteoporosis.  "We are close

to identifying a unique bone structure gene for osteoporosis," Chief

Executive Officer John Padfield told Reuters.  "All other treatments try to

stop bone loss getting worse. What our gene appears to do is increase bone

density very substantially,  if this turns out to be true when we test a

drug, that would be a revolutionary treatment for osteoporosis."  The

company announced the discoveries as part of a day-long update on its

research and development activities. Shares in Chiroscience were up seven

percent or 17 1/2 pence in early afternoon trading in London.  Chiroscience

said it will also work with the small British genome company Gemini

Research, which has built up a database of genetic information based on

identical twins. The two companies are to look for mutant genes linked to

obesity.

LOS ANGELES (Reuters) - Researchers said Monday they had discovered a

technique that might eventually be able to prevent kidney damage caused in

many patients by the autoimmune disease lupus.  Scientists at the

University of California, Los Angeles, identified a sequence of amino acids

that sets off a chain of events in the body that causes kidney damage. They

then injected mice with the amino acids to induce tolerance so the body did

not react to the harmful protein in the future.  Mice in the control group

died on average after 35 weeks, while 80% of mice who had been treated were

still alive at 60 weeks, with the majority of them having no kidney damage.

Lupus, which causes inflammation of various organs,  affects more than 1

million Americans. It can cause arthritis, skin rashes and strokes, destroy

heart valves and trigger a variety of other problems.  About 5% of lupus

patients suffer kidney damage that either kills them or requires dialysis.

"A similar strategy might be developed to use in therapy of human lupus,"

said Dr. Bevra Hahn of UCLA, who led the research team. Hahn presented her

findings at the annual meeting of the American College of Rheumatology in

San Diego. 

Survival rates of lupus have improved in recent years. The disease can be

treated with cortisone and chemotherapy drugs, but those drugs suppress the

entire immune system, thereby increasing the possibility of potentially

fatal infections. If Hahn's research eventually led to a treatment for

humans, it would have the advantage of not suppressing the overall immune

system. But it takes years of research to translate findings in mice into

treatments for humans, and most breakthroughs in animal tests eventually

fail in humans.

King of Prussia, PA.,11/20/98: PRNewswire: A Virginia woman's heart valve

damage lawsuit, which was scheduled for trial Dec. 7 against the makers of

fenfluramine, has settled for a confidential amount, Mealey Publications

has reported (Sabine Sisk v. A.H. Robins Company Inc., No. 971062, Va.

Cir., Alexandria City).  Had it proceeded to trial, the action filed by

Sabine Sisk would have been the first fen-phen trial against pharmaceutical

companies.  A.H. Robins Company Inc., Wyeth-Ayerst Laboratories and

American Home Products Corp. were the remaining defendants; Sisk had

previously voluntarily dismissed the phentermine defendants.  The lawsuit

was also notable because Sisk was one of the 24 patients in the initial

Mayo Clinic study on fen-phen use and heart valve damage.  Sources said

Sisk was Patient No. 4 in that study, which appeared in the Aug. 28, 1997,

issue of The New England Journal of Medicine.  Sisk, who is in her early

50s, sued in December 1997, alleging that she ingested Pondimin and

phentermine between May 1995 and May 1996.  Sisk underwent surgery to

repair her mitral valve and is now partially disabled.  Her lawsuit sought

$5 million in compensatory and punitive damages, plus interest.

Durham, NC: (Reuters): High amounts of an amino acid commonly found in the

blood of elderly people may be associated with Alzheimer's disease,

researchers reported Sunday. The findings are important because they

provide a hypothesis that it may be possible to prevent Alzheimer's disease

from developing in some potential sufferers since the amino acid can be

lowered by taking folic acid, said A. David Smith, a researcher. Smith and

Robert Clarke reported on a study of 164 patients aged 55 and older who had

Alzheimer's-type dementia. They found elevated levels of homocysteine in

the patients' blood.

M Howse,  L Bindoff,  A Carmichael, South Tees Acute Hospitals Trust,

Middlesbrough TS4 3BW  UK: We report a case of facial vasculitic rash

associated with intravenous immunoglobulin to show that intravenous

immunoglobulin should be added to the list of drugs that can precipitate

cutaneous vasculitis.  A 30 year old woman presented with an 18 month

history of slowly progressive dysaesthesia of her arms and legs and

weakness of her feet and hands. She was not taking any drugs and did not

have a history of atopy or rashes. Chronic inflammatory demyelinating

polyneuropathy was confirmed electromyelographically. Erythrocyte

sedimentation rate, C reactive protein, thyroid function, blood glucose

concentration, serum vitamin B-12 concentration, results of protein

electrophoresis, cerebrospinal fluid constituents, results of syphilis

serology, urinary porphyrin concentrations, and concentrations of

antinuclear antibody, extractable nuclear antigen antibodies, neutrophil

cytoplasmic antibody & ganglioside antibody were all normal or negative.

She was treated with intravenous human immunoglobulin (Sandoglobulin) 0.4

g/kg/day for five days.

On the third day of treatment she developed an itchy papular facial rash,

which deteriorated over the next week, extending to her upper back and

palms. Some lesions developed non-blanching purpura and others painful

superficial skin necrosis. She was not feverish and was systemically well.

Urine analysis gave negative results. A skin biopsy specimen showed a

leucocytoclastic vasculitis and no granulomata. The rash resolved with

clobetasone butyrate cream (Eumovate) twice a day and cetirizine 10 mg

daily for a week, leaving a few areas of scarring. The rash did not recur

over the next six months. In view of the severity of the reaction,

rechallenge was not considered to be ethical. 

LABS:  Another valuable resource for those wishing to find out just what

their implants are or to validate their condition:  mtr@resch.com 402)

476-7616, (402) 476-7637 Resch Engineering, Inc.  (Michael Resch) 227 N.

9th Street, Suite 200, Lincoln, NE 68508

ALTERNATIVE MEDICINE.  Harvesting the Fruit of Letting Go (Bastyr

University)  Melody Beattie:  LETTING GO...WITH LOVE:  whenever possible,

be gentle with yourself and others.  Find the balance between assertive

action taken in our own best interest, and love for others. Our path can be

a gentle one, walked in love, learning to set boundaries and detach.

LETTING GO...OF SADNESS:  Many of us didn't have the tools, support or

safety we needed to acknowledge and accept pain and sadness in our past.

It's okay.  Now we can begin the process of feeling what we have denied for

so long.  It's okay to cry and feel the sadness many of us have stored for

so long.  We can feel and release those feelings.  LETTING GO ...OF FEAR:

Fear can motivate us to control situations or neglect ourselves. We may

have relied on fear to protect ourselves.  But now, we can choose to live

life differently.  It's time to thank our old fears for helping us survive,

then wave good-bye to them...and welcome peace, trust, acceptance and

safety.  LETTING GO ...OF GUILT:  the things we feel guilty about are not

always our issues.  Another person may behave inappropriately or in some

way violate our boundaries.  We challenge their behavior, they get angry

and defensive...then we feel guilty. Guilt can prevent us from setting the

boundaries that would be in our best interests.  Guilt can stop us from

taking healthy care of ourselves.  We don't have to be controlled by

guilt...we can let go of our guilty feelings and trust ourselves to know

when our boundaries are being violated.  LETTING GO...OF A NEED TO CONTROL:

Letting go of our need to control can set us and others free.  The rewards

from detachment are great...serenity; a deep sense of peace; the ability to

give and receive love in self-enhancing energizing ways; and the freedom to

find real solutions to our problems.  LETTING GO ...OF PERFECTION:  Stop

expecting perfection from yourself and those around you.  Our expectations

need to be reasonable...and expecting perfection is not reasonable.  Have,

and set boundaries.  Have reasonable expectations.  Strive to do your

best...and encourage others to do the same, but know that we and others

will make mistakes... know that we and others will have learning

experiences.  LETTING GO...SELF DOUBT  Many of us, so confident about our

ability to take care of others, doubt our inherent strength to care for

ourselves.  We may have come to believe, from past or present

circumstances, that we need to take care of others and we need them to take

care of us.  No matter where this self defeating belief was born, we can

release it and replace it with a better one, a healthier one, a more

accurate one...WE CAN TAKE CARE OF OURSELVES, whether we are in or out of a

relationship.  LETTING GO...OF ANGER  Anger is a powerful and sometimes

frightening emotion.  It can be beneficial, if it's not allowed to harden

into resentment or used as a battering ram to punish or abuse people.

Anger is a warning signal.  It points to problems needing to be solved; it

points to boundaries we need to set; or it may be the final burst of energy

before "letting go" or acceptance settles in.  Remember to breathe deeply.

We can shamelessly feel all our feelings, including anger. We can take

responsibility for our behavior and learn to release our feelings in a

healthy way. ("the language of letting go" by Melody Beattie).

Cellular and Humoral Immunity:  White blood cells (WBCs) can be considered

the soldiers of the immune system. They are manufactured in the bone

marrow, and mature cells constitute five different types: lymphocytes,

monocytes, basophils, neutrophils, and eosinophils. Mature WBCs "wiggle"

out of blood vessels into intercellular spaces filled with tissue fluid.

Here they can move freely to protect all tissues. The WBCs differentiate

into many forms, giving the immune defense force an impressive array of

physical and chemical weapons.

Some lymphocytes migrate into lymphatic tissues including the thymus and

lymph nodes. Here they are transformed into T-cells and B-cells that

provide cellular immunity to these organs. T-cells form several highly

specialized subsets including T-helper, T-suppresser, T-cytotoxic, T-4, and

T-8 cells. T-cells produce hormone-like proteins called cytokines, some of

which are interferon, interleukin and tumor necrosis (killing) factor.

B-cells turn into plasma cells that produce antibodies-including

immunoglobulins such as IgA, IgG and IgM--in response to an unwelcome

antigen. Antibodies "remember" the antigen and make it difficult for it to

get very far the next time it tries to enter the body. This gives the body

future protection against the outsider and is called humoral immunity.

Further differentiation of lymphocytes produces natural killer (NK) cells

that specialize in destruction of foreign cells like cancer when in the

presence of interferon.   Monocytes swell into larger cells, called

macrophages, once they enter the tissue fluid. Some macrophages attach

themselves to strategic locations on tissues, while others roam about.

These large, active cells are constantly on the alert and are the first to

react when encountering infection or trauma. They initially form a rosette

shape, indicating their alarm, and then send a chemical message, the

enzymatic complement system, to other WBCs, alerting them to come quickly

and attack the invader.

After basophils migrate into intercellular spaces they form mast cells.

These proliferate in the presence of sensitizing allergens and release a

protein called histamine. Histamine's role is to protect the body, but

allergic over-sensitization of the immune response often makes histamine

seem like an enemy.  Neutrophils function like scouts and foot soldiers

that rove about in search of bacteria and viruses that have entered the

body. These are the WBCs "notified" by macrophages when danger is present.

Once invaders are identified, the neutrophils move in to destroy the

invaders.  Eosinophils may, unfortunately, be familiar to most of us

because these are the WBCs that increased dramatically in the group of

people who had taken contaminated L-tryptophan. Eosinophils respond when

chemical contaminants enter the body. Their job is to participate in the

inflammatory response that will remove the toxic threat. As we know, the

contaminant, not L-tryptophan, triggered the release of large numbers of

eosinophils.

8/13/98 Vertigoheel(R): Shown to be Safe and Effective in the Treatment of

Vertigo:  A study published in the August issue of the American Medical

Association Journal Archives of Otolaryngology - Head and Neck Surgery

shows that Vertigoheel(R), a prescription homeopathic medication, is as

effective and safe as betahistine, a histamine analogue considered standard

therapy in Europe for the management of vertigo symptoms.   The publication

of this study in an AMA journal reflects the growing interest in

homeopathic medicine. In fact, in the July 15, 1998 issue of the Journal of

the American Medical Association (JAMA), a survey of readers identified

"alternative medicine" such as homeopathy, as one of the top ten topics of

which more information should be published.

Vestibular or balance disorders such as vertigo, dizziness, and motion

sickness affect approximately two million people in the U.S. Despite the

severity of vertigo, American physicians lack a conventional medication

proven to be an effective treatment for the disease. This study represents

the first equivalence trial comparing a homeopathic treatment for vertigo

to standard drug therapy.   "This is the first time that the AMA has

published a study of a homeopathic drug, a study that was designed

according to modern scientific methodology," said Dana Ullman, MPH,

president of the Foundation for Homeopathic Education and Research, and

author of numerous books on homeopathy. "Other respected, peer-reviewed

medical publications such as The Lancet, Pediatrics and British Medical

Journal are now joined by the AMA's Archives of Otolaryngology in their

scientific review of homeopathic studies."

Spray starch contains silicone.  Check labels.

Brain Injury: When brain injury occurs, irrespective of the cause, brain

blood flow is either directly or indirectly altered and almost invariably

decreased.  In the region of the injury there is a continue decrease in

blood flow between the high flow at the edge of the wound to the absence of

blood flow in the center of the wound.   The compromised blood flow implies

that there is a simultaneous decrease in blood pressure along the affected

vessels as well as a decrease in the oxygen delivered to the cells supplied

by those affected blood vessels.  Significantly decreased blood flow,

accompanied by marked decreases in available oxygen , is referred to as

ischemia.  Research in animals and humans showed that when the available

oxygen fall below a certain minimal level, the nerve cells, although alive,

become sluggish in their metabolism and can no longer conduct bio-electric

impulses.    Brain cells which cannot conduct bio-electric impulses behave

as if they are metabolically sluggish and electrically non-functioning are

called idling neurons.  The region of the wound in which idling neurons are

located is referred to as the ischemic penumbra.  As the available oxygen

and blood flow drop by an additional 50% and the nerve cells eventually

die.  The amount of brain tissue that dies depends primarily on the extent

of damage to and interference with brain blood flow.  With tiny wounds,

such as may be seen in certain cases of brain decompression sickness, there

is less likelihood that the cells will die.  However, with large wounds in

the brain, such as occur in major strokes, a fair amount of brain tissue

dies. However, all brain injuries have varying amounts of ischemic

penumbral areas containing idling neurons.  Idling neurons may remain

quiescent for  years.

How Oxygen Works:  The exact mechanism whereby oxygen exerts its beneficial

effects on the brain is not known.  It, too, is under investigation. The

investigators think that oxygen is working in the brain in a fashion

similar to the way it works in the treatment of other wounds.  Oxygen is

know to stimulate:  1. The metabolism of nerve cells that have been

deprived of oxygen. 2. The removal of toxic metabolic products or waste. 3.

The efficiency of cells that clean out damaged and dead tissue. 4. The

number of cells that produce new connective tissue in the cleaned out

areas.  5. The amount of new connective tissue to fill in the empty spaces.

6. The formation of new blood vessels that will provide a continuous

source of oxygen, nutrients and the removal of waste products for all the

new cells that have been formed.  Neurbauer and Gorrlieb, based on their

clinical studies have found that in their experience has supported the

hypothesis in that patients with chronic brain injury or various etiologies

have responded favorably to HYPERBARIC Oxygen Therapy (HBOT).

In California, check out this address for hyperbaric help at a reasonable

cost.  Susan is a silicone survivor who trained and opened a clinic for us.

The address is:  Rapid Recovery Hyperbarics, 1455 N Waterman Ave

124,125,126, San Bernardino, CA.  hyperbaric1@earthlink.net     (909) 989-3378

INFORMATION AVAILABLE:  Too good to be true????????  10-3-98: New Herbal

Product Featured on the Maury Povich Show Causes Women's Breasts To Grow!

Las Vegas' own Angela Harris appeared on the Maury Povich show on July

28th, 1998. She spoke about her revolutionary new product, Grobust. Yes, it

does what its name says, it causes women's breasts to grow.  Maury Povich

says that the most-asked-about product that he has ever featured on the

show was the Grobust. The show was literally inundated with telephone calls

for weeks after the show. Angela Harris is truly a remarkable woman. She

was on Maury's Home Remedies show to briefly discuss the Grobust product,

but there is more to the story than that! She was diagnosed with deadly

lymphoma when she was pregnant with her 6th child. She refused traditional

treatment, and instead opted for alternative herbal treatments. In effect,

she ended up curing her own cancer, and now has 7 children. She works

throughout the United States and Mexico teaching cancer patients her

methods and is responsible for saving many lives!  She also works with

women who are unable to conceive, helping them to balance their hormones,

and has a VERY high success rate. In working with these women, one of the

outstanding results, (other than successful pregnancies), is the fact that

they all increased their bust size. Hence, she refined and perfected an

herbal product that causes women's breasts to grow. This is noteworthy

because many women are so desperate to increase their breast size they are

resorting to mutilating their own bodies with implant surgery. Angela's

success rate has been 90%, at a fraction of the cost of implant surgery.

Since we have been working with women and this new herbal product, it has

become painfully obvious that this is a VERY serious problem. What was once

thought of as a vanity issue, it is now known to be much more important

than that. Many times a day, we have women call us who are in obvious

mental anguish. They will not wear a bathing suit, they cannot look at

themselves in the mirror, they will not undress in front of their husbands,

or worse yet, they will not allow themselves to get close to a man, all

because of their insecurities because of their small breasts.  We have

"saved" many women from undergoing the dangerous implant surgery and would

like to get the word out even more. Angela is available for television or

radio interviews. If you would like more information about the Grobust and

the remarkable success she has had with women enlarging their breast size

1-3 cup sizes without invasive surgery, please do not hesitate to contact

me.  Warmest regards, Karen Sheldon  (800) 887-9130

IMPORTANT:   Health and Medical Issues in the News:  Are Researchers PAID

Off?  The health implications of PAID are indeed worrisome, particularly

the potential for research bias.  This patient, er, doctor exhibits an

advanced case of Pecuniary Associated Infectious Disease. (A.

Shepherd/ABCNEWS.com)  By Nicholas Regush ABCNEWS.com: This menace to

public health is known as PAID (Pecuniary Associated Infectious Disease).

In recent years, there have been outbreaks, and, of late, members of the

medical research community appear to be falling victim, like flies to

sticky tape. The cause of PAID? It's believed to be fistfuls of research

money, along with special consulting trips to Europe, Hawaii and Asia and

an assortment of trinkets (like computers) for educational review. The

suppliers are corporations that manufacture drugs, medical devices and the

like.  Tell-tale PAID Symptoms:  A possible cofactor for the disease is the

pursuit of recognition within the research ranks, which is mainly realized

by heavily sponsored travel to special conferences where learned

commentaries can be imparted in the limelight.  Afterwards, there  will be

special meals, along with treats for spouses. This is all known as PAID

Status. One of the early symptoms of PAID is the belief  by the recipients

of these special benefits that their research will in no way be influenced

by the expectations of their benefactors. This is known as PAID Denial. At

this stage of progression, typical pronouncements include "I am fully

capable of withstanding any pressure from my sponsors, and, I can be truly

objective."  One recent instance of PAID Denial made the news when three

doctors editorialized in the British Medical Journal against the idea that

Prozac and similar antidepressant drugs are addictive, a controversial

issue. When it was later  learned that Prozac's manufacturer, Eli Lilly,

had sponsored the doctors trip to a symposium in Phoenix, some observers

naturally wondered about their editorial stance. One of the authors told

the journal that he didn't think his relationship with Lilly was important.

Typical.  You Scratch My Back, I'll Scratch Yours.  A sure sign that PAID

is highly infectious comes from the study published this year in the New

England Journal of Medicine, showing that the vast majority of authors who

backed a controversial group of heart disease drugs called calcium channel

blockers had financial relationships with manufacturers of these products.

Most didn¼t even think of disclosing the ties. Such group behavior is known

as PAID Spread.  In contrast, among those critical of the drugs, there were

far fewer financial relationships with the companies.  I think I know what

may lie at the core of PAID:  The afflicted are actually embarrassed to

tell all, particularly when they wish to express a strong point of view

about a product. For example, sometimes receive letters from irate medical

researchers questioning the intelligence of reports that I produce for

World News Tonight with Peter   Jennings.  A little bit of digging usually

reveals that  the researchers have financial ties with companies whose

products are under scrutiny. In other words, PAID Secrets. 

PAID Promotion is the stage reached when the researcher with company

backing ends up hyping the very same product he or she was testing.

Implications and Treatment.  The health implications of PAID are indeed

worrisome, particularly the potential for research bias, which, in turn,

might lead to exaggerated claims of benefit for a product and minimization

of safety issues.   Fortunately, there is now much discussion of    PAID in

the medical literature. And there is   financial ties that may inhibit

complete consideration of the scientific picture. It's late in the epidemic

for  excuses.    Unfortunately, there is no reliable treatment for PAID.

Dr. George Lundberg, editor of the Journal of  the American Medical

Association, has stated that the issue of financial disclosure is broad and

difficult and that many journals have strict guidelines. Absolutely true.

Nonetheless, epidemics require aggressive surveillance. Perhaps the medical

journals could all try a little harder to ferret out PAID Secrets.

Otherwise, we all  start to think that the drug ads which help them keep

publishing are somehow PAID related.  Medical researchers and journal

publishers aren't the only ones affected by PAID. Next  we all look at how

PAID affects medical reporting.     (Nicholas Regush)

BOOKS: A new breast implant book is out:  Silicone Spills: Breast Implants

on Trial by Mary White Stewart. It is published by Praeger Press of

Greenwood Publishing Group in Westport, CT. You can find this book at

Barnes & Noble or on the internet at Amazon.com  Mary is a professor at a

Univ. In Nevada and her brother is an attorney.

THIS MONTH'S POEM:

            Truth in Science?

          By Lynda Roth

Well, I guess I should be disillusioned

Or angry, or frustrated, or more.

Or maybe I should just ignore it

(I know I've done that before.)

I can't say that I'm surprised

Though disappointed I certainly am

For an opportunity again has been lost

To expose this breast implant scam.

Once again we've been ignored

(Did they really want to see?)

For a veritable treasure trove

Our medical records could be!

Biased studies will never bring truth

And ignoring us won't make us leave.

For truth will out-no matter what

Even though the companies'deceive.

Truth has a way of finding a path

Time will be shown as a friend

For those who doubt our resolve

To you, this message we send.

Even the National Science Panel

Will not suppress what we know

Nothing has changed, we are still sick

And we have a lot to show.

Our words will never be squelched

And our fight will never end

When one tires, two more stand up

This deception to transcend.

So keep your biased science

Keep your lies and your deceit

The fight is just beginning

Your corruption to defeat.

Your denials still continue

You've gone to extreme lengths

But you underestimate our will

You just don't know our strength.

While today you may seem strong

We've had our day before.

Truth is always on our side

We'll even up the score.

THE OPINIONS EXPRESSED IN THIS NEWSLETTER ARE THOSE OF THE EDITOR AND ANY

CONTRIBUTORS AND ARE NOT TO BE CONSTRUED AS MEDICAL OR LEGAL ADVICE.  ANY

ARTICLES OR INFORMATION SUBMITTED MAY BE EDITED BECAUSE OF SPACE, CONTENT

OR GRAMMATICAL ERRORS.

LYNDA ROTH, EDITOR

PREVIOUS NEWSLETTER INFORMATION: Previous issues of newsletters available:

$2 each U.S., $3 Foreign.  1/93 is the first available issue.  Please

indicate months' desired and proper sums.  Some covered subjects:

Auto-immune 1/93; Fibromyalgia 2/93; Medical Testing 3/93; Sjogren's 4/93;

Vasculitis 4/93; Arthritis 5/93; Chronic Fatigue 6/93; Lupus 7/93;

Irritable Bowel Syndrome & Inflammatory Bowel Disease 8/93; Insurance 8/93,

9/93; Misc. Med. Info. 9/93; Multiple Sclerosis 10/93; Spasmodic

Torticollis 10/93; Hypoglycemia 11/93; Antibodies 12/93; Reflex Sympathetic

Dystrophy 1/94; Misc. Med. Info. II 2/94; Scleroderma 3/94; Costochondritis

4/94; Peripheral Neuropathy 4/94; Class Action 5/94; Fungal Infections

6/94;  Hypercalcemia (low calcium) 7/94; Raynaud's Phenomenon 8/94;

Fibromyalgia Update 9/94;  Sarcoidosis 10/94; Free Radicals 11/94;

Porphyria 12/94; Interstitial Cystitis 1/95; Mixed Connective Tissue

Disease 2/95; Flap Procedures 3/95;  Misc. Med. 4/95; Thyroid Disease 5/95;

Stress 6/95; Natural Healing 7/95; Adrenal Malfunctions 8/95; Multiple

Myeloma 9/95; DHEA 10/95; Chelation Therapy 11/95; Sleep Disorders 12/95;

Meniere's Disease 1/96; 33 Tips to Improve Your Health 2/96; Amino Acids

3/96; Enzymes 4/96; Minerals 5/96; Aluminum Toxicity, DHEA Update 6/96;

Addictions & Food Sensitivities 7/96; Misc. Med. Info. IV 8/96; Misc. Med.

Info. V 9/96; Misc. Med. Info. VI 10/96; Misc. Med. Info. VII 11/96;

Transcient Ischemic Attacks 12/96; Symptoms of Breast Implant Problems

1/97; Pap Tests 2/97; Parasitic Infections 3/97; B-Complex Deficiency

Syndrome 4/97; Myofascial Pain Syndrome 5/97; Inositol 6/97; Misc. Med.

Info. VIII 7/97; High Blood Pressure 8/97; Plaquenil 9/97; Misc. Med. Info.

IX 10/97; Misc. Med. Info. X 11/97; Gastroesophageal or acid reflux 12/97;

Smoking Dangers 1/98; Misc. Med XI  2/98; Multiple

Chemical Sensitivities 3/98; Misc. Med. XII 4/98; Misc. Med. XIII 5/98;

Baylor Studies 6/98; Hyperbaric Oxygen 7/98; IOM Summaries 8/98; CFS 9/98;

Trace Metal Toxicology 10/98; Restless Leg Syndrome, Tamoxifen 11/98;

Legal info. and info. on  Alternative Medicine Info. contained in most issues.

NEWSLETTER SUBSCRIPTION INFORMATION Check your mailing label for expiration

date.  The date is right after your name.  We are unable to notify you

individually of expiration dates. If your expiration date says Dec.'98,

that is the last newsletter you will receive without a renewal.

Please return bottom portion with check or Money Order for renewal or

include the pertinent information with check or M.O. for $25.

THANKS TO THE TWO PEOPLE WHO DONATED TO HELP FIX THE FAX MACHINE, IT WILL

BE UP AND RUNNING AGAIN SOON!  PLEASE HELP US MAKE IT ANOTHER YEAR! WE NEED

YOUR TAX-EXEMPT DONATION NOW! WOMEN CALL DAILY IN NEED OF HELP!!  THIS

BATTLE NEEDS YOU!!!!!   AND ME!!!!!

Please return this portion with your subscription or renewal or include the

pertinent data with your check or money order.

Name

____________________________________________________________________________

_______________________________________________________

Annual Subscriptions:  Individual ($25.00 U.S.-- $35.00 Foreign

(U.S.Funds)_________________________________________________________________

____

Address_____________________________________________________________________

______________________________________________________

Phone___________________________________________________________FAX_________

_____________________________________________________ 

Prior

newsletters-Month,Yr._______________________________________________________

____Amount  Enclosed (U.S. Funds)_______________________

Mail to:    Coalition of Silicone Survivors (COSS)             The

Coalition of Silicone Survivors is a not-for-profit, tax-exempt corporation.

            PO Box 129, Broomfield, Co. 80038-0129            Donations are

tax-deductible in the U.S. and gratefully accepted!

LR